-
Company Profile
![]()
TRACON Pharmaceuticals Inc – Company Profile
TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: MeiraGTx Holdings Plc’s AAV-AQP1
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TILT-123 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TILT-123 in Peritoneal Cancer Drug Details:TILT-123 is under development for the treatment of metastatic melanoma, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACU-193 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ACU-193 in Alzheimer's Disease Drug Details:ACU-193 is under development for the treatment of Alzheimer's disease and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STI-6129 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.STI-6129 in Refractory Multiple Myeloma Drug Details:Monoclonal antibody conjugate is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Methoxyamine Hydrochloride in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Methoxyamine Hydrochloride in Solid Tumor Drug Details: TRC-102 (methoxyamine hydrochloride) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Geptanolimab in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Geptanolimab in Non-Small Cell Lung Cancer Drug Details:Geptanolimab (CBT-501) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pelcitoclax in Peripheral T-Cell Lymphomas (PTCL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Pelcitoclax in Peripheral T-Cell Lymphomas (PTCL) Drug Details:Pelcitoclax (APG-1252) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Vulvar Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Vulvar Cancer Drug Details: XmAb-717 is under development for the treatment of cervical...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Soft Tissue Sarcoma Drug Details: Envafolimab (Enweida) is a recombinant humanized single domain...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Fibrosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Fibrosarcoma Drug Details: Envafolimab (Enweida) is a recombinant humanized single domain antibody against...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Pleomorphic Liposarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Pleomorphic Liposarcoma Drug Details: Envafolimab (Enweida) is a recombinant humanized single domain antibody...
-
Product Insights
Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. The Myocardial Fibrosis pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally,...
-
Thematic Analysis
![]()
State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you - Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months. Understand the most impactful emerging technologies - Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
![]()
Net Present Value Model: Methoxyamine Hydrochloride
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Methoxyamine Hydrochloride Drug Details TRC-102 (methoxyamine...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
![]()
Net Present Value Model: Enweida
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Enweida Drug Details Envafolimab (Enweida) is...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – TRC-253
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TRC-253 Drug Details TRC-253 is under development for the treatment of metastatic castrate-resistant prostate...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.